[Effect of atorvastatin on the nuclear factor-kappaB and soluble inter-cellular adhesion molecules-1 in patients with acute coronary syndrome].
OBJECTIVE
To determine the effect of atorvastatin on the activity of peripheral blood lymocyte nuclear factor-kappaB (NF-kappaB) and plasma soluble inter-cellular adhesion molecules-1 (sICAM-1) in acute coronary syndromes.


METHODS
Sixty-eight patients with acute coronary syndrome were randomly divided into atorvastatin therapeutic group (n = 37) and conventional therapeutic group (n = 31). Enzyme-linked immunosorbent assay was used to measure the plasma sICAM-1, and immunohistochemical method was used to measure the activity of NF-kappaB in the peripheral blood lymphocyte before and 12 weeks after the therapy in the two groups.


RESULTS
Before the therapy, the level of NF-kappaB activity in the peripheral blood lymphocytes [(45.2 +/- 8.4)% vs (40.8 +/- 9.2)%, P > 0.05] and the plasma sICAM-1 [(357.2 +/- 84.5) ng/ml vs (365.5 +/- 91.3) ng/ml, P > 0.05] in the two groups had no significant difference. After 12 weeks of the therapy, in the conventional group the level of NF-kappaB activity in the peripheral blood lymphocytes [(40.8 +/- 9.2)% vs (38.7 +/- 8.9)%, P > 0.05] and the plasma sICAM-1 [(357.2 +/- 84.5) ng/ml vs (365.5 +/- 91.3) ng/ml, P > 0.05] still had no significant difference. But in the atorvastatin group the level of NF-kappaB activity in the peripheral blood lymphocyte [(45.2 +/- 8.4)% vs (25.6 +/- 7.9)%, P < 0.05 and the plasma soluble inter-cellular adhesion molecule-1 [(357.2 +/- 84.5) ng/ml vs (175.8 +/- 75.6) ng/ml, P < 0.05] did show a significant difference.


CONCLUSIONS
The cholesterol-lowering therapy with atorvastatin can reduce the inflammation and stabilize the plaque in the acute coronary syndrome, which may be related to the inhibition of NF-KB and sICAM-1 activities.
Luo
Ying
Y
Department of Gerontology, Xiangya Hospital, Central South University, Changsha 410008, China.
Xie
Xiu-Mei
XM
Liu
Hui-Xia
HX
D000368:Aged; D000789:Angina, Unstable / Q000188:drug therapy* / Q000378:metabolism; D000924:Anticholesteremic Agents / Q000627:therapeutic use; D000069059:Atorvastatin; D005260:Female; D006538:Heptanoic Acids; D006801:Humans; D018799:Intercellular Adhesion Molecule-1 / Q000097:blood*; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000188:drug therapy* / Q000378:metabolism; D016328:NF-kappa B / Q000097:blood*; D011758:Pyrroles
D000924:Anticholesteremic Agents; D006538:Heptanoic Acids; D016328:NF-kappa B; D011758:Pyrroles; D018799:Intercellular Adhesion Molecule-1; D000069059:Atorvastatin